Table 5 Changes from baseline in SGRQ and SF-36 scores*
From: One-year treatment with mometasone furoate in chronic obstructive pulmonary disease
|  | MF-DPI†| Placebo†| MF-DPI – Placebo | |||
|---|---|---|---|---|---|---|
| Â | n | Mean | n | Mean | Mean | P value |
SGRQ scores | Â | Â | Â | Â | Â | Â |
   Total | 504 | -3.92 | 241 | -0.64 | -3.28 | 0.003 |
   Activity | 506 | -4.20 | 242 | -1.05 | -3.15 | 0.021 |
   Impacts | 516 | -2.81 | 244 | -0.25 | -2.58 | 0.031 |
   Symptoms | 534 | -7.21 | 248 | -2.26 | -4.95 | 0.004 |
SF-36 PCS score | 503 | 1.05 | 235 | 0.01 | 1.04 | 0.050 |
SF-36 MCS score | 503 | 0.25 | 235 | -0.32 | 0.57 | 0.372 |